DFX Intelligence
Borrowers
80 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Health Care Equipment & Services” (remove)
Start from
80 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| BVI Medical, Inc Life sciences | unattributed | 11 | at least $548M | 87c | 10 pts | Mar 1, 2032 | Sep 30, 2022 |
| ACI Group Holdings, Inc Life sciences | unattributed | 9 | at least $516M | 70c | n/a | Aug 1, 2027 | Dec 31, 2021 |
| Plasma Buyer LLC Life sciences | Sponsor not establishedpossible: Primus Capital Partners, Inc. (a company of this name is on the sponsor's portfolio page) | 13 | at least $413M | 57c | 7 pts | Mar 1, 2027 | Dec 31, 2021 |
| P•••••• A••••••••• T•••• S•••••• Life sciences | unattributed | 6 | at least $337M | 100c | 1 pts | Jan 1, 2028 | Dec 31, 2021 |
| N•••••• P•••••••• L•• Life sciences | unattributed | 8 | at least $248M | 101c | 1 pts | Nov 1, 2030 | Dec 31, 2021 |
| O••• B•••••••• L•• Life sciences | unattributed | 13 | at least $205M | 100c | 2 pts | Apr 26, 2029 | Dec 31, 2021 |
| C•••••• L•• Life sciences · grade B | unattributed | 1 | at least $188M | 100c | n/a | Jun 18, 2029 | Jun 30, 2024 |
| P••••••••• Life sciences | unattributed | 1 | at least $185M | 102c | n/a | Oct 15, 2032 | Dec 31, 2025 |
| P••• L•• Life sciences | Sponsor not establishedpossible: G•••••• C•••••• (a company of this name is on the sponsor's portfolio page) | 6 | at least $178M | 100c | n/a | Mar 1, 2028 | Dec 31, 2021 |
| A••••••• V••••• P••••••• Life sciences | Sponsor not establishedpossible: H••••• C••••••• L•• (a company of this name is on the sponsor's portfolio page) | 2 | at least $101M | 100c | 0 pts | Sep 1, 2026 | Dec 31, 2021 |
| H•••••••• B••••• I•• Life sciences | unattributed | 5 | at least $92.7M | 100c | 1 pts | Sep 29, 2027 | Dec 31, 2024 |
| A•• H••••••• I• C••• Life sciences | unattributed | 6 | at least $88.8M | 90c | n/a | Feb 1, 2028 | Sep 30, 2022 |
| H•••••• C••• B••••• I•• Life sciences | Sponsor not establishedpossible: B•••••••• E••••• P••••••• L•• (a company of this name is on the sponsor's portfolio page) | 3 | at least $73.3M | 101c | 1 pts | Mar 31, 2028 | Dec 31, 2021 |
| D••••• C••• A••••••• I•• Life sciences | unattributed | 3 | at least $73.1M | 101c | n/a | Jun 1, 2031 | Dec 31, 2021 |
| A••••••• D••••••••• • C••••••• S•••••• Life sciences | unattributed | 4 | at least $53.7M | 93c | n/a | Aug 1, 2026 | Dec 31, 2021 |
| S•• C•••• Life sciences | unattributed | 1 | at least $51.4M | 97c | n/a | Oct 24, 2032 | Dec 31, 2025 |
| M••••• A••••••••• C••• Life sciences | unattributed | 4 | at least $46.0M | 101c | n/a | Oct 1, 2027 | Sep 30, 2023 |
| A••••••••• C••• I•• Life sciences | unattributed | 5 | at least $45.4M | 101c | n/a | Jun 1, 2031 | Dec 31, 2020 |
| E••••••• I•••••••• I•• Life sciences | unattributed | 3 | at least $41.2M | 81c | 5 pts | Jun 28, 2029 | Sep 30, 2022 |
| O•• C••• C••• M••••••••• I•• Life sciences | unattributed | 1 | at least $40.9M | 103c | n/a | May 1, 2032 | Dec 31, 2020 |
| E•• S••••••• I•• Life sciences | Sponsor not establishedpossible: B••••• W••• C••••••• L•• (a company of this name is on the sponsor's portfolio page) | 1 | at least $40.0M | 101c | n/a | Jun 15, 2027 | Dec 31, 2022 |
| G•••••• L•• Life sciences · grade B | unattributed | 1 | at least $38.2M | 79c | n/a | Feb 1, 2027 | Sep 30, 2022 |
| R•••• 9• M••••••• I•• Life sciences | Sponsor not establishedpossible: I••••••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $35.0M | 101c | n/a | Mar 31, 2029 | Dec 31, 2022 |
| H••••••• I••••••••• L•• E•• Life sciences | unattributed | 1 | at least $26.6M | n/a | n/a | Sep 9, 2032 | Sep 30, 2025 |
| M•••••••• S••••••• I•• Life sciences | unattributed | 1 | at least $25.0M | 106c | n/a | Aug 18, 2028 | Jun 30, 2026 |
| S••••• R••••••••• L•• Life sciences | unattributed | 2 | at least $21.9M | 72c | n/a | Dec 29, 2028 | Dec 31, 2022 |
| S••••• S•••••• H••••••• A••••••••• I•• Life sciences | unattributed | 2 | at least $19.8M | 101c | 0 pts | Mar 20, 2030 | Jun 30, 2024 |
| P•••••• D••••• C••• M••••••••• L•• Life sciences | unattributed | 1 | at least $18.1M | 100c | n/a | Aug 31, 2027 | Dec 31, 2022 |
| M•• D••••• Life sciences | W•••••• P••••• L•• inferred | 3 | at least $17.3M | 101c | 0 pts | Feb 13, 2031 | Dec 31, 2023 |
| O••••• M•••••• Life sciences | unattributed | 1 | at least $17.1M | 104c | n/a | Jun 15, 2028 | Jun 30, 2024 |
| S••••• U• B•••• C••• Life sciences · grade B | unattributed | 1 | at least $15.5M | 105c | n/a | Jul 31, 2029 | Dec 31, 2022 |
| C•• T• M••••• S••• L•• Life sciences | unattributed | 1 | at least $15.0M | 100c | n/a | May 31, 2029 | Jun 30, 2023 |
| B••••••••• I•• Life sciences | unattributed | 1 | at least $13.8M | 101c | n/a | May 15, 2027 | Jun 30, 2026 |
| P••••••••• I••••••••• L• Life sciences | H•••••• I••••••••• M••••••••• L••••• inferred | 3 | at least $13.6M | 101c | n/a | Sep 30, 2027 | Dec 31, 2022 |
| S••••••••• I••••••••• Life sciences | unattributed | 1 | at least $13.1M | 101c | n/a | Dec 31, 2029 | Dec 31, 2022 |
| C•••••• S••••••••• H•••••••• L•• Life sciences | unattributed | 1 | at least $12.4M | 100c | n/a | Jun 30, 2027 | Dec 31, 2022 |
| G••••• S•••• B••••• I•• Life sciences | unattributed | 7 | at least $12.1M | 100c | n/a | Apr 2, 2031 | Dec 31, 2021 |
| I••••••••• I•• Life sciences | unattributed | 1 | at least $11.5M | 109c | n/a | Feb 5, 2030 | Jun 30, 2026 |
| H••••••• P••••••• M••••••••• L•• Life sciences | unattributed | 1 | at least $11.5M | 101c | n/a | May 31, 2027 | Dec 31, 2022 |
| M•••••• R••••• I•••••••• o• A•••••• Life sciences | Sponsor not establishedpossible: P•••••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 3 | at least $11.2M | 100c | 0 pts | Jul 31, 2030 | Mar 31, 2024 |
| U•••••• V••••• P••••••• Life sciences | Sponsor not establishedpossible: W••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $11.0M | 99c | n/a | Sep 30, 2027 | Dec 31, 2022 |
| G•••••••• M•••••• S•••••••• L•• Life sciences | unattributed | 1 | at least $9.6M | 58c | n/a | Jun 30, 2026 | Dec 31, 2022 |
| A•••••• H••••• Life sciences | Sponsor not establishedpossible: L•••••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 1 | at least $8.3M | 101c | n/a | Feb 28, 2029 | Mar 31, 2024 |
| L••••••••• L•• S••••••• Life sciences | unattributed | 1 | at least $6.7M | 100c | n/a | Oct 31, 2027 | Mar 31, 2023 |
| H••••••• I••••••••• L•• G•• Life sciences | unattributed | 1 | at least $6.6M | n/a | n/a | Sep 9, 2032 | Sep 30, 2025 |
| R•• B••••••••• H•••••• L•• Life sciences | unattributed | 1 | at least $6.6M | 101c | n/a | Dec 31, 2030 | Dec 31, 2024 |
| C• A••••• M••••••••• L•• Life sciences | unattributed | 1 | at least $6.6M | 101c | n/a | Aug 31, 2027 | Mar 31, 2023 |
| N•••••• C••• P••••••• H•••••••• I•• Life sciences | unattributed | 1 | at least $6.5M | 101c | n/a | Oct 1, 2030 | Dec 31, 2024 |
| C••••••••• Life sciences | Sponsor not establishedpossible: W••••••• C•••••• P••••••• L•• (a company of this name is on the sponsor's portfolio page) | 1 | at least $6.1M | 98c | n/a | Jun 30, 2029 | Mar 31, 2023 |
| A••••••••• L•• Life sciences | Sponsor not establishedpossible: L••••• M•••••• P••••••• L•• (a company of this name is on the sponsor's portfolio page) | 1 | at least $5.9M | 100c | n/a | Oct 31, 2029 | Dec 31, 2023 |
Page 1 of 2Next
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.